Members
Margin of Safety Dashboard
Finch Trades
Research Notes
Coverage Ecosystem
My Profile
Logout
Why Join?
Member Benefits
Public
Articles
Data Visualizations
Newsletter
Newsletter
About
What Is Solt DB?
Public Benefit
Our Lonely Team
Pricing
Login
Newsletter
My Profile
Login
Finch Trades
As of market close
August 28, 2026
Update frequency: every Saturday morning
Transaction
Position
Overall
Group
Year
Company
Ticker
Entry Date
Group
Status
Cost Basis
Last Price
Principal
Last Value
% Change
vs. SPY
Click individual row to view transaction details
BridgeBio Oncology Therapeutics
$BBOT
7/8/26
Future Compounder
Active
Exited
9986
$8.74
$8.74
$500
$500
0.0%
-2.8%
Relay Therapeutics
$RLAY
5/19/26
Future Compounder
Active
Exited
9987
$12.31
$18.77
$950
$1,449
52.5%
48.1%
Relay Therapeutics
$RLAY
5/18/26
Future Compounder
Active
Exited
9988
$12.32
$18.77
$2,500
$3,809
52.4%
48.4%
Relay Therapeutics
$RLAY
5/5/26
Future Compounder
Active
Exited
9989
$12.95
$18.77
$2,500
$3,624
44.9%
38.9%
Relay Therapeutics
$RLAY
3/13/26
Future Compounder
Active
Exited
9990
$10.40
$18.77
$1,250
$2,256
80.5%
64.5%
Relay Therapeutics
$RLAY
3/12/26
Future Compounder
Active
Exited
9991
$10.40
$18.77
$1,250
$2,256
80.5%
65.4%
Coherus Oncology
$CHRS
3/6/26
Future Compounder
Active
Exited
9992
$1.75
$1.2160
$2,500
$1,737
-30.5%
-45.1%
Codexis
$CDXS
3/2/26
Future Compounder
Active
Exited
9993
$1.00
$1.59
$1,000
$1,590
59.0%
46.9%
Harmony Biosciences
$HRMY
2/20/26
Opportunistic
Active
Exited
9994
$30.75
$28.50
$1,750
$1,622
-7.3%
-7.4%
Harmony Biosciences
$HRMY
5/2/25
Current Compounder
Active
Exited
9995
$30.00
$28.50
$23,245
$22,083
-5.0%
-25.7%
Exact Sciences
$EXAS
4/30/25
Opportunistic
Active
Exited
9999
$44.69
$53.05
$10,000
$11,871
18.7%
14.9%
Blueprint Medicines
$BPMC
4/30/25
Opportunistic
Active
Exited
10000
$88.21
$98.73
$10,000
$11,193
11.9%
8.9%
Coherus Oncology
$CHRS
3/27/25
Future Compounder
Active
Exited
$0.86
$1.2200
$250
$355
42.0%
5.8%
Coherus Oncology
$CHRS
1/21/25
Future Compounder
Active
Exited
$1.37
$1.2200
$1,000
$891
-10.9%
-39.1%
Relay Therapeutics
$RLAY
1/10/25
Future Compounder
Active
Exited
$4.32
$18.77
$7,000
$30,428
334.7%
302.2%
AVITA Medical
$RCEL
1/8/25
Future Compounder
Active
Exited
9998
$9.53
$7.45
$1,000
$782
-21.8%
-18.5%
Relay Therapeutics
$RLAY
12/10/24
Future Compounder
Active
Exited
$4.44
$18.77
$2,500
$10,557
322.3%
294.7%
Relay Therapeutics
$RLAY
12/3/24
Future Compounder
Active
Exited
$4.45
$18.77
$2,500
$10,557
322.3%
294.9%
Relay Therapeutics
$RLAY
11/20/24
Future Compounder
Active
Exited
$4.55
$18.77
$2,000
$8,252
312.6%
282.3%
Relay Therapeutics
$RLAY
10/29/24
Future Compounder
Active
Exited
$5.80
$18.77
$1,000
$3,239
223.9%
191.7%
Arrowhead Pharma
$ARWR
10/1/24
Future Compounder
Active
Exited
9996
$18.48
$63.64
$1,000
$3,444
244.4%
224.2%
Relay Therapeutics
$RLAY
9/25/24
Future Compounder
Active
Exited
$7.00
$18.77
$725
$1,944
168.1%
133.2%
Arrowhead Pharma
$ARWR
9/25/24
Future Compounder
Active
Exited
9997
$19.48
$63.64
$1,000
$3,268
226.8%
206.9%
Relay Therapeutics
$RLAY
9/13/24
Future Compounder
Active
Exited
$7.55
$18.77
$1,000
$2,486
148.6%
111.7%
Relay Therapeutics
$RLAY
9/5/24
Future Compounder
Active
Exited
$6.18
$18.77
$2,000
$6,074
203.7%
163.7%
Coherus Oncology
$CHRS
7/2/24
Future Compounder
Active
Exited
$1.40
$1.2200
$1,000
$875
-12.5%
-53.3%
Exact Sciences
$EXAS
5/29/24
Current Compounder
Active
Exited
$44.98
$105.00
$1,000
$2,334
133.4%
108.8%
Relay Therapeutics
$RLAY
5/29/24
Future Compounder
Active
Exited
$6.28
$18.77
$1,000
$2,991
199.1%
152.9%
Coherus Oncology
$CHRS
4/25/24
Future Compounder
Active
Exited
$1.93
$1.2109
$6,996
$4,390
-37.3%
-90.7%
Position
Ticker
Group
Status
Shares
Cost Basis
Last Price
Principal
Last Value
% Change
vs. SPY
Click individual row to view position details
Cash
Cash
$27,579
Relay Therapeutics
$RLAY
Future Compounder
Building
Building
Building
1
4,790.8
$5.88
$18.77
$28,175
$89,923
219.2%
193.8%
Codexis
$CDXS
Future Compounder
Building
Building
Building
2
1,000.0
$1.00
$1.59
$1,000
$1,590
59.0%
46.9%
BridgeBio Oncology Therapeutics
$BBOT
Future Compounder
Full
Full
Full
4
57.2
$8.74
$8.74
$500
$500
0.0%
-2.8%
Coherus Oncology
$CHRS
Future Compounder
Exited
Exited
Exited
993
6,791.3
$1.73
$1.21
$11,746
$8,247
-29.8%
-71.4%
Harmony Biosciences
$HRMY
Opportunistic
Exited
Exited
Exited
994
56.9
$30.75
$28.50
$1,750
$1,622
-7.3%
-7.4%
Harmony Biosciences
$HRMY
Current Compounder
Exited
Exited
Exited
995
774.8
$30.00
$28.50
$23,245
$22,083
-5.0%
-25.7%
Exact Sciences
$EXAS
Current Compounder
Exited
Exited
Exited
996
22.2
$44.98
$105.00
$1,000
$2,334
133.4%
108.8%
Arrowhead Pharma
$ARWR
Future Compounder
Exited
Exited
Exited
997
105.5
$18.96
$63.64
$2,000
$6,712
235.6%
206.9%
AVITA Medical
$RCEL
Future Compounder
Exited
Exited
Exited
998
104.9
$9.53
$7.45
$1,000
$782
-21.8%
-18.3%
Exact Sciences
$EXAS
Opportunistic
Exited
Exited
Exited
999
223.8
$44.69
$53.05
$10,000
$11,871
18.7%
14.9%
Blueprint Medicines
$BPMC
Opportunistic
Exited
Exited
Exited
1000
113.4
$88.21
$98.73
$10,000
$11,193
11.9%
8.9%
$53,153
Principal
$119,592
Current Value
125.0%
Total Return
(from April 2024)
41.4%
CAGR
(from April 2024)
Benchmark
Ticker
Principal
Current Value
$ Change
% Change
Finch Trades vs.
Finch Trades
$FINCH
$53,153
$119,592
$66,440
125.0%
0.0%
If S&P 500
$SPY
$53,153
$69,799
$16,646
31.3%
93.7%
If XBI
$XBI
$53,153
$92,373
$39,221
73.8%
51.2%
If Nasdaq 100
$QQQ
$53,153
$75,710
$22,557
42.4%
82.6%
If ARKG
$ARKG
$53,153
$97,053
$43,900
82.6%
42.4%
Group
Principal
Last Value
% Change
vs. SPY
vs. QQQ
vs. XBI
vs. ARKG
Future Compounder
$44,421
$107,754
142.6%
114.4%
105.5%
82.8%
64.1%
Opportunistic
$21,750
$24,686
13.5%
10.3%
11.6%
13.3%
13.0%
Current Compounder
$24,245
$24,417
0.7%
-20.2%
-23.6%
-50.8%
-30.6%
* This view tracks performance by the portfolio allocation group without accounting for reinvested proceeds.
Year
Principal
Last Value
% Change
vs. SPY
vs. QQQ
vs. XBI
vs. ARKG
2024
$23,721
$60,411
154.7%
116.8%
103.8%
82.5%
72.2%
2025
$52,495
$77,602
47.8%
32.4%
30.0%
12.3%
19.4%
2026
$14,200
$18,843
32.7%
24.4%
23.1%
9.4%
-24.3%
* This view tracks performance by the year principal was invested without accounting for reinvested proceeds.
Research Notes
MOS Dashboard